Breaking News

Financial Report: Bristol-Myers Squibb

April 26, 2013

Avapro, Plavix expirations pummel results

Bristol-Myers Squibb

1Q Revenues: $3.8 billion (-27%)
 
1Q Earnings: $623 million (-58%)
 
Comments: Revenues were pounded by patent expiration for Avapro/Avalide (-78%) in March 2012 and Plavix (-95%) in May 2012. U.S. sales decreased 44% to $2.0 billion. International net sales increased 6% to $1.9 billion. Baraclude sales were up 13% to $366 million. Erbitux sales were down 9% to $162 million. Sprycel sales were up 24% to $287 million. Yervoy sales were up 49% to 229 million. Abilify sales were down 16% to 52 million. Orencia sales were up 26% to $320 million. R&D expenses increased 2% to $930 million in the quarter.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks